IRP Activity and Ferritin Content in Monocytes From Controls and GH Patients Treated With Cytokines
| . | Medium . | LPS/IFN-γ . | LPS/IFN-γ/NMMA . | SNAP . | LPS/IFN-γ/DFO . |
|---|---|---|---|---|---|
| Control subjects (n = 16) | |||||
| IRP (%) | 100 | 47 ± 12* | 94 ± 16 | 43 ± 9* | 146 ± 21* |
| Ft content (ng/mg prot.) | 620 ± 257 | 798 ± 232† | 667 ± 321 | 803 ± 221† | 482 ± 52† |
| GH patients (n = 12) | |||||
| IRP (%) | 100 | 93 ± 16 | 97 ± 14 | 91 ± 11 | 153 ± 19* |
| Ft content (ng/mg prot.) | 1023 ± 627 | 1124 ± 735 | 1107 ± 642 | 1078 ± 756 | 651 ± 32* |
| . | Medium . | LPS/IFN-γ . | LPS/IFN-γ/NMMA . | SNAP . | LPS/IFN-γ/DFO . |
|---|---|---|---|---|---|
| Control subjects (n = 16) | |||||
| IRP (%) | 100 | 47 ± 12* | 94 ± 16 | 43 ± 9* | 146 ± 21* |
| Ft content (ng/mg prot.) | 620 ± 257 | 798 ± 232† | 667 ± 321 | 803 ± 221† | 482 ± 52† |
| GH patients (n = 12) | |||||
| IRP (%) | 100 | 93 ± 16 | 97 ± 14 | 91 ± 11 | 153 ± 19* |
| Ft content (ng/mg prot.) | 1023 ± 627 | 1124 ± 735 | 1107 ± 642 | 1078 ± 756 | 651 ± 32* |
Monocytes from control subjects and GH patients were left untreated (medium) or treated for 24 hours with 100 U/mL IFN-γ plus 1 μg/mL LPS, in the presence and absence of 0.1 mmol/L NMMA and 0.05 mmol/L Desferrioxamine (DFO). Cells were also incubated with 0.5 mmol/L SNAP for 24 hours. IRP activity was quantitated by liquid scintillation counting. Ferritin content was measured by a radioimmunoassay based on antihuman liver ferritin antibody. Values are given as mean ± SD.
P < .001 versus controls.
P < .05 versus controls.